The primary treatment of<unk>  is discontinuation of the causative factor(s), usually an offending drug, early referral and management in burn units or intensive care units, supportive management, and nutritional support. Current literature does not convincingly support use of any adjuvant systemic therapy. Initial interest in Intravenous immunoglobulin (IVIG) came from research showing that IVIG could inhibit Fas-FasL mediated keratinocyte apoptosis in vitro. Unfortunately, research studies reveal conflicting support for use of IVIG in treatment of<unk> . Ability to draw more generalized conclusions from research to date has been limited by lack of controlled trials, and inconsistency in study design in terms of disease severity, IVIG dose, and timing of IVIG administration. Larger, high quality trials are needed to assess the actual benefit of IVIG in<unk> . Numerous other adjuvant therapies have been tried in<unk>  including, corticosteroids, ciclosporin, cyclophosphamide, plasmapheresis, pentoxifylline, acetylcysteine, ulinastatin, infliximab, and granulocyte colony-stimulating factors (if<unk>  associated-leukopenia exists). There is mixed evidence for use of corticosteroids and scant evidence for the other therapies. A meta-analysis from 2002 concluded that there is no reliable evidence for the treatment of<unk> . Thalidomide did not show any benefit and was associated with increased mortality compared with placebo.
Toxic epidermal necrolysis
Staphylococcal scalded skin syndrome
Poikiloderma vasculare atrophicans
Chickenpox
Streptococcal intertrigo
Skin condition
Cutaneous lupus mucinosis
Staphylococcal infection